135 PROTEIN PROVISION AND EXERCISE THERAPY TO IMPROVE OUTCOMES IN ICU-SURVIVORS 7 DISCUSSION Discussion 23a Provide a general interpretation of the results in the context of other evidence. 4.0 discussion 4.1 interpretation of the results 23b Discuss any limitations of the evidence included in the review. 4.2 methodological considerations and limitations 23c Discuss any limitations of the review processes used. 4.2 methodological considerations and limitations 23d Discuss implications of the results for practice, policy, and future research. 4.3 implication of the results; 5.0 conclusion OTHER INFORMATION Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state that the review was not registered. 2.1 protocol and registration 24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. 2.1 protocol and registration 24c Describe and explain any amendments to information provided at registration or in the protocol. n.a. Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. Funding statement Competing interests 26 Declare any competing interests of review authors. Conflict of interest Availability of data, code and other materials 27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. Supplementary data From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 For more information, visit: http://www.prisma-statement.org/
RkJQdWJsaXNoZXIy MjY0ODMw